BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35975564)

  • 1. Protective effects of Panax ginseng against doxorubicin-induced cardiac toxicity in patients with non-metastatic breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
    Hamidian M; Foroughinia F; Haghighat S; Attar A; Haem E
    J Oncol Pharm Pract; 2023 Sep; 29(6):1306-1316. PubMed ID: 35975564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
    Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
    Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study.
    Mohamed AL; El-Abd AA; Mohamed HG; Noufal AM; Hennawy BS
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102130. PubMed ID: 37858847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study.
    Foulkes SJ; Howden EJ; Haykowsky MJ; Antill Y; Salim A; Nightingale SS; Loi S; Claus P; Janssens K; Mitchell AM; Wright L; Costello BT; Lindqvist A; Burnham L; Wallace I; Daly RM; Fraser SF; La Gerche A
    Circulation; 2023 Feb; 147(7):532-545. PubMed ID: 36342348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
    Heck SL; Mecinaj A; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; Røsjø H; Steine K; Geisler J; Gulati G; Omland T
    Circulation; 2021 Jun; 143(25):2431-2440. PubMed ID: 33993702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
    Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
    Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
    Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of exercise training on cardiac toxicity markers in women with breast cancer undergoing chemotherapy with anthracyclines: a randomized controlled trial.
    Antunes P; Joaquim A; Sampaio F; Nunes C; Ascensão A; Vilela E; Teixeira M; Capela A; Amarelo A; Marques C; Viamonte S; Alves A; Esteves D
    Eur J Prev Cardiol; 2023 Jul; 30(9):844-855. PubMed ID: 36857149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
    Yu AF; Moore ZR; Moskowitz CS; Liu JE; Dang CT; Ramanathan L; Oeffinger KC; Steingart RM; Schmitt AM
    JAMA Cardiol; 2023 Jul; 8(7):697-702. PubMed ID: 37256614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
    Thavendiranathan P; Houbois C; Marwick TH; Kei T; Saha S; Runeckles K; Huang F; Shalmon T; Thorpe KE; Pezo RC; Prica A; Maze D; Abdel-Qadir H; Connelly KA; Chan J; Billia F; Power C; Hanneman K; Wintersperger BJ; Brezden-Masley C; Amir E
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):515-525. PubMed ID: 37120736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
    Neilan TG; Quinaglia T; Onoue T; Mahmood SS; Drobni ZD; Gilman HK; Smith A; Heemelaar JC; Brahmbhatt P; Ho JS; Sama S; Svoboda J; Neuberg DS; Abramson JS; Hochberg EP; Barnes JA; Armand P; Jacobsen ED; Jacobson CA; Kim AI; Soumerai JD; Han Y; Friedman RS; Lacasce AS; Ky B; Landsburg D; Nasta S; Kwong RY; Jerosch-Herold M; Redd RA; Hua L; Januzzi JL; Asnani A; Mousavi N; Scherrer-Crosbie M
    JAMA; 2023 Aug; 330(6):528-536. PubMed ID: 37552303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
    Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
    J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.
    Howden EJ; Bigaran A; Beaudry R; Fraser S; Selig S; Foulkes S; Antill Y; Nightingale S; Loi S; Haykowsky MJ; La Gerche A
    Eur J Prev Cardiol; 2019 Feb; 26(3):305-315. PubMed ID: 30376366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
    Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
    BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial.
    Nabati M; Janbabai G; Esmailian J; Yazdani J
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):233-241. PubMed ID: 30599756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of Echocardiography and Cardiac Magnetic resonance in assessing left ventricular function in breast and gastric cancer patients after Anthracycline Chemotherapy.
    Jin CL; Shi XG; Wang TT; Li HW; Zhang DX; Sheng Z; Xiao J; Yu YQ
    BMC Cardiovasc Disord; 2023 Sep; 23(1):465. PubMed ID: 37715125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
    Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.